A Clinical registry study of Liao-Shi-Hua-Feng-Dan for stroke
- Conditions
- Stroke
- Registration Number
- ITMCTR2200006753
- Lead Sponsor
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. Conform to the diagnostic criteria for acute ischemic stroke in the Chinese guidelines for diagnosis and treatment of acute Ischemic Stroke 2018, or conform to the diagnostic criteria for cerebral hemorrhage in the Chinese guidelines for diagnosis and treatment of acute intracerebral hemorrhage 2019. Conform to the Diagnostic Efficacy Assessment Criteria for Stroke in 1995.
2. The enrolled patients were hospitalized;
3. The enrolled patients were patients with limb pain after stroke or numbness of limbs after stroke or limb spasms after stroke, and patients treated with Hua Fengdan;
4. The patient gives informed consent and signs the informed consent form.
1. Those who are allergic to the drug
2. Those with combined serious diseases of liver, kidney, hematopoietic system, endocrine system and osteoarthrosis, psychiatric disease.
3. Subjects who have difficulty cooperating to complete the neurological function and other assessments related to this study,or the clinical investigator judges that it is difficult for subjects to complete the evaluation and follow-up for other reasons.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Visual Analogue Scale/Score;Fugl-Meyer assessment scale;Modified Ashworth Scale;
- Secondary Outcome Measures
Name Time Method Investigation of diagnostic information of stroke in traditional Chinese medicine;safety indexes;Adverse event;Modified Rankin Scale;National Institute of Health stroke scale;Complications after stroke;Fugl-Meyer motor assessment;